Akane Yamamoto

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Yuta Nakamura, Ichiro Horie, Tadahiro Kitamura, Yoshiki Kusunoki, Kenro Nishida, Akane Yamamoto, Yushi Hirota, Tomoyasu Fukui, Yasutaka Maeda, Masae Minami, Takanori Matsui, Atsushi Kawakami, Norio Abiru
Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study. Diabetes, obesity & metabolism 26 (5) (2024)
Yuta Nakamura, Ichiro Horie, Tadahiro Kitamura, Yoshiki Kusunoki, Kenro Nishida, Akane Yamamoto, Yushi Hirota, Tomoyasu Fukui, Yasutaka Maeda, Masae Minami, Takanori Matsui, Atsushi Kawakami, Norio Abiru
Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study. Diabetes, obesity & metabolism (2024)
Yuta Nakamura, Ichiro Horie, Tadahiro Kitamura, Yoshiki Kusunoki, Kenro Nishida, Akane Yamamoto, Yushi Hirota, Tomoyasu Fukui, Yasutaka Maeda, Masae Minami, Takanori Matsui, Atsushi Kawakami, Norio Abiru
Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study. Diabetes, obesity & metabolism 26 (5) (2024)
Yuta Nakamura, Ichiro Horie, Tadahiro Kitamura, Yoshiki Kusunoki, Kenro Nishida, Akane Yamamoto, Yushi Hirota, Tomoyasu Fukui, Yasutaka Maeda, Masae Minami, Takanori Matsui, Atsushi Kawakami, Norio Abiru
Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study. Diabetes, obesity & metabolism 26 (5) (2024)